Johnson & Johnson (NYSE:JNJ) Shares Acquired by Piscataqua Savings Bank

Posted by Defense World Staff on Apr 13th, 2023

Piscataqua Savings Bank increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,322 shares of the company’s stock after purchasing an additional 100 shares during the period. Johnson & Johnson makes up approximately 4.4% of Piscataqua Savings Bank’s investment portfolio, making the stock its 3rd largest holding. Piscataqua Savings Bank’s holdings in Johnson & Johnson were worth $5,180,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Veracity Capital LLC increased its position in Johnson & Johnson by 1.2% during the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after buying an additional 59 shares during the last quarter. Sandy Cove Advisors LLC increased its position in Johnson & Johnson by 1.6% during the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock worth $605,000 after buying an additional 60 shares during the last quarter. LCM Capital Management Inc increased its position in Johnson & Johnson by 0.7% during the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock worth $1,667,000 after buying an additional 61 shares during the last quarter. Paces Ferry Wealth Advisors LLC increased its position in Johnson & Johnson by 0.7% during the third quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after buying an additional 62 shares during the last quarter. Finally, Mason & Associates Inc increased its position in Johnson & Johnson by 4.9% during the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after buying an additional 62 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.2 %

Shares of NYSE:JNJ opened at $163.92 on Thursday. The business’s 50 day simple moving average is $157.44 and its 200 day simple moving average is $167.03. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $186.69. The company has a market capitalization of $426.90 billion, a P/E ratio of 24.32, a P/E/G ratio of 2.85 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The firm had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period in the prior year, the company earned $2.13 earnings per share. The company’s quarterly revenue was down 4.4% on a year-over-year basis. On average, research analysts anticipate that Johnson & Johnson will post 10.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on JNJ. SVB Leerink lowered their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. UBS Group initiated coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price on the stock. Atlantic Securities upped their target price on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research report on Wednesday, January 25th. Piper Sandler decreased their target price on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Finally, Morgan Stanley decreased their target price on Johnson & Johnson from $180.00 to $179.00 and set an “equal weight” rating on the stock in a research report on Monday. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $173.07.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Johnson & Johnson (NYSE:JNJ) Shares Acquired by Piscataqua Savings Bank

Johnson & Johnson Trading Down 0.2 %

Insiders Place Their Bets

Analyst Upgrades and Downgrades

About Johnson & Johnson

Further Reading

You might be interested in: